103 related articles for article (PubMed ID: 5728154)
1. Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.
Loo TL; Luce JK; Jardine JH; Frei E
Cancer Res; 1968 Dec; 28(12):2448-53. PubMed ID: 5728154
[No Abstract] [Full Text] [Related]
2. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
3. Disposition of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, a new antitumor agent.
Housholder GE; Loo TL
J Pharmacol Exp Ther; 1971 Nov; 179(2):386-95. PubMed ID: 5133607
[No Abstract] [Full Text] [Related]
4. Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-aminoimidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Biochem Pharmacol; 1970 Jun; 19(6):2043-51. PubMed ID: 5513972
[No Abstract] [Full Text] [Related]
5. Comparative effects of the antitumor agents 5-(Dimethyltriazeno)-imidazole-4-carboxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L1210 leukemia cells in vivo.
Shirakawa S; Frei E
Cancer Res; 1970 Aug; 30(8):2173-90. PubMed ID: 5459764
[No Abstract] [Full Text] [Related]
6. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel CL; Denham C; Waalkes TP; DeVita VT
Cancer Res; 1970 Jun; 30(6):1651-7. PubMed ID: 5457935
[No Abstract] [Full Text] [Related]
7. 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)--clinical brochure.
Carter SK; Newman JW
Cancer Chemother Rep 3; 1968 Dec; 1(1):63-80. PubMed ID: 4989815
[No Abstract] [Full Text] [Related]
8. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel CL; DeVita VT; Denham C; Foley HT; Field RB; Carbone PP
Cancer Chemother Rep; 1971 Apr; 55(2):159-65. PubMed ID: 5118685
[No Abstract] [Full Text] [Related]
9. Adaptation of a colorimetric determination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) and 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) to blood.
Field RB; Hoffman G; Waravdekar VS; Kline I
Cancer Chemother Rep; 1969 Jun; 53(3):199-202. PubMed ID: 4980814
[No Abstract] [Full Text] [Related]
10. Antitumor activity of imidazole derivatives, especially of 2',3',5'-tri-o-formyl beta-D-ribofuranosyl 5-formamido 4-imidazolethiocarboxamide.
Hoshi A; Osaka Y; Nishimoto T; Kanzawa F; Kuretani K
Gan; 1970 Aug; 61(4):383-7. PubMed ID: 5503251
[No Abstract] [Full Text] [Related]
11. Prostatic effects of cis-diamine-chloroplatinum in the dog.
Varkarakis MJ; Murphy GP
Res Commun Chem Pathol Pharmacol; 1972 Sep; 4(2):433-8. PubMed ID: 5074534
[No Abstract] [Full Text] [Related]
12. In vitro primary antitumor screen of imidazole platinum complexes.
Kuduk-Jaworska J
Arch Immunol Ther Exp (Warsz); 1994; 42(1):77-82. PubMed ID: 7503641
[TBL] [Abstract][Full Text] [Related]
13. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties.
Marriott MS; Baird JR; Brammer KW; Faulkner JK; Halliwell G; Jevons S; Tarbit MH
Dermatologica; 1983; 166 Suppl 1():1-7. PubMed ID: 6884559
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
[No Abstract] [Full Text] [Related]
16. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in mammalian cells in culture.
Gerulath AH; Loo TL
Biochem Pharmacol; 1972 Sep; 21(17):2335-43. PubMed ID: 4675028
[No Abstract] [Full Text] [Related]
18. Synthesis and biological evaluation of analogues of the anti-tumor alkaloid naamidine A.
Aberle N; Catimel J; Nice EC; Watson KG
Bioorg Med Chem Lett; 2007 Jul; 17(13):3741-4. PubMed ID: 17462892
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
20. Automated simultaneous blood glucose and urea determination.
Hunter WH
J Med Lab Technol; 1967 Oct; 24(4):293-300. PubMed ID: 6052975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
